Short-term efficacy and safety of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma regardless of cisplatin eligibility
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: This study aimed to evaluate the short-term efficacy and safety of enfortumab vedotin plus pembrolizumab (EV + P) as a first-line systemic therapy for patients with advanced urothelial carcinoma (UC) in real-world practice, with a focus on cisplatin (CDDP) eligibility. METHODS: Seventy-six patients who received EV + P treatment for advanced UC at 13 institutions between November 2024 and March 2025 were retrospectively included in this study. We collected the clinical characteristics and treatment data of the patients and assessed treatment response, progression-free survival (PFS), and adverse events (AEs). Patients were divided into two groups based on CDDP eligibility, and both efficacy and safety were compared between the groups. RESULTS: The median observation period was 5.56 (IQR, 4.77-6.21) months. Complete response was achieved in 6 (7.9%) patients receiving EV + P, partial response in 40 (52.6%), stable disease in 20 (26.3%), and progressive disease in 10 (13.2%). Six-month and median PFS rates were 80.6% and not reached, respectively. AEs of any grade and grade ≥3 occurred in 59 (77.6%) and 25 (32.9%) patients, respectively. The most frequently observed AE was skin disorders, which occurred in 36 (47.4%) patients; no grade 5 AEs were observed. Treatment response, PFS, and the cumulative incidence of AEs did not differ between CDDP-ineligible and CDDP-eligible patients. CONCLUSIONS: The short-term efficacy of EV + P treatment seemed comparable to that in previous reports, and the safety profile was acceptable, regardless of CDDP eligibility.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Short-term efficacy and safety of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma regardless of cisplatin eligibility
- Date Crossref
- 20/07/2026
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The University of Osaka Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Osaka International Cancer Institute Department of Urology pays non établi dans la noticeÉtablissement de santé
-
Osaka Rosai Hospital Department of Urology pays non établi dans la noticeÉtablissement de santé
-
Osaka City General Hospital pays non établi dans la noticeÉtablissement de santé
-
Toyonaka Municipal Hospital Department of Urology pays non établi dans la noticeÉtablissement de santé
-
Sakai Municipal Hospital pays non établi dans la noticeÉtablissement de santé
-
Osaka Hospital pays non établi dans la noticeÉtablissement de santé
-
Minoh City Hospital Department of Urology pays non établi dans la noticeÉtablissement de santé
-
Hyogo Prefectural Nishinomiya Hospital Department of Urology pays non établi dans la noticeÉtablissement de santé
-
Ikeda Municipal Hospital pays non établi dans la noticeÉtablissement de santé
-
Nippon Life Hospital Department of Urology pays non établi dans la noticeÉtablissement de santé
-
Higashiosaka College & Higashiosaka Junior College pays non établi dans la noticeUniversité ou école supérieure
Department of Urology — The University of Osaka, Department of Urology — Osaka International Cancer Institute et Department of Urology — Osaka Rosai Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.